Results 131 to 140 of about 33,791,512 (292)
Inspired by the germination of probiotic spores, we utilize the excellent characteristics of spores to break through multiple barriers of oral brain‐targeted delivery. Besides the probiotics mediated gut‐brain communication, the spore coat proteins derived nanosystems with multiple‐barriers‐crossing ability alleviate neurodegeneration.
Qianhua Feng +9 more
wiley +1 more source
Body‐integrated photonic biosensors: Illuminating the path to active healthcare
Body‐integrated photonic biosensors are promising tools for active healthcare. These optical devices can be worn, implanted, or swallowed to monitor health signals continuously. This review introduces key sensing modalities, including fluorescence, colorimetry, SPR, LSPR, SERS, and light‐modulating materials.
Jiayue Gu +10 more
wiley +1 more source
Effects of digestive products of quinoa, oat, barley, and mungbean proteins on GLP‐1 secretion are investigated using STC‐1 cell and animal experiments, and novel GLP‐1 secretion‐stimulating peptides are successfully identified by column chromatography and LC–MS/MS.
Hongdong Song +8 more
wiley +1 more source
Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
Hamish Courtney,1 Rahul Nayar,2 Chinnadorai Rajeswaran,3 Ravi Jandhyala 4 1Diabetes Department, Royal Victoria Hospital, Belfast, 2City Hospitals Sunderland NHS Foundation Trust, Sunderland, 3Department of Diabetes & Endocrinology, Mid Yorkshire NHS ...
Rajeswaran C +3 more
core
Circadian rhythm disruption impairs metabolic regulation, appetite control, and vascular function, promoting obesity and cardiovascular diseases. Evidence highlights a bidirectional relationship where metabolic disorders further disturb circadian timing.
Ghizal Fatima +4 more
wiley +1 more source
Effect of Glucagon‐Like Peptide 1 Receptor Agonists on Obstructive Sleep Apnea
Background and Aim Glucagon‐like peptide‐1 receptor (GLP‐1R) agonists are well‐established therapies for obesity and type 2 diabetes mellitus (T2DM). Emerging evidence also suggests their potential role in managing obstructive sleep apnea (OSA).
Bei‐Bei Qian +4 more
doaj +1 more source
Heather L Gelhorn,1 Elizabeth D Bacci,2 Jiat Ling Poon,1 Kristina S Boye,3 Shuichi Suzuki,4 Steven M Babineaux3 1Outcomes Research, Evidera, Bethesda, MD, 2Evidera, Seattle, WA, 3Global Patient Outcomes and Real World Evidence, Eli Lilly and Company ...
Suzuki S +5 more
core
ABSTRACT Background Akkermansia muciniphila has emerged as a leading next‐generation beneficial microbe candidate in gut microbiome research, linked to host metabolic homeostasis, mucosal immune regulation, and intestinal barrier integrity. However, marked methodological heterogeneity in isolation and culture conditions, detection and quantification ...
Jiaxin Chen, Mantang Qiu
wiley +1 more source
Association Between Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Arrhythmias
Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), initially designed to treat diabetes mellitus (DM), have demonstrated the potential to mitigate obesity‐related cardiovascular risks.
Vikash Jaiswal +12 more
doaj +1 more source

